Cargando…

A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine

Parents indicate that safety is their top concern about human papillomavirus (HPV) vaccination. A data-mining method not requiring prespecification of health outcome(s) or postexposure period(s) of potentially increased risk can be used to identify possible associations between an exposure and any o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yih, W Katherine, Kulldorff, Martin, Dashevsky, Inna, Maro, Judith C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245868/ https://www.ncbi.nlm.nih.gov/pubmed/33558897 http://dx.doi.org/10.1093/aje/kwab022

Ejemplares similares

A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
por: Yih, W Katherine, et al.
Publicado: (2022)

Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System
por: Yih, W Katherine, et al.
Publicado: (2018)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

Statistical Power for Postlicensure Medical Product Safety Data Mining
por: Maro, Judith C., et al.
Publicado: (2017)

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2017)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
por: Wan, Yuehua, et al.
Publicado: (2022)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women()
por: Ruiz-Sternberg, Ángela María, et al.
Publicado: (2017)

Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries
por: Garland, S M, et al.
Publicado: (2018)

A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink
por: Yih, W. Katherine, et al.
Publicado: (2023)

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
por: SIGNORELLI, C., et al.
Publicado: (2017)

Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series
por: Wenande, Emily, et al.
Publicado: (2021)

The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2021)

Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021
por: Chen, Fuxing, et al.
Publicado: (2022)

Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium
por: Simoens, Steven, et al.
Publicado: (2021)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes
por: Kharbanda, Elyse O., et al.
Publicado: (2021)

Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant
por: Wyant, W. Austin, et al.
Publicado: (2022)

Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
por: Nolan, Katrina M., et al.
Publicado: (2023)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study
por: Amend, Kandace L., et al.
Publicado: (2022)

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results
por: Baker, Meghan A., et al.
Publicado: (2019)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
por: Thiem, Vu Dinh, et al.
Publicado: (2021)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
por: Serrano, Beatriz, et al.
Publicado: (2012)

Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient
por: Nichols, Anna J., et al.
Publicado: (2020)

5. Observational Study of Routine Use of 9-Valent Human Papillomavirus Vaccine: Safe in More Than 140,000 Individuals
por: Hansen, John, et al.
Publicado: (2020)

A broadly protective vaccine against cutaneous human papillomaviruses
por: Mariz, Filipe Colaco, et al.
Publicado: (2022)

Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis
por: Jiang, Y, et al.
Publicado: (2019)

2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
por: Arana, Jorge, et al.
Publicado: (2018)

Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study
por: Rahman, Shams, et al.
Publicado: (2016)

The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
por: Mahumud, Rashidul Alam, et al.
Publicado: (2019)

Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System
por: Yih, Weiling Katherine, et al.
Publicado: (2015)

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
por: Olsson, Sven-Eric, et al.
Publicado: (2020)

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types
por: Tanton, Clare, et al.
Publicado: (2017)

Correction: The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_309pnpmdd69erc97sbi9o8kn2p